OUR PRODUCTS

MOBILE APPS

GENERAL INFO

CRDF

Stock ticker: NASDAQ

PRICE

CHANGE

CAPITALIZATION

Cardiff Oncology (CRDF) Earnings Date & Reports

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

CRDF is expected to report earnings to fall 2.95% to -20 cents per share on October 30

Cardiff Oncology CRDF Stock Earnings Reports

Q3'25

Est.

$-0.20

Q2'25

Missed

by $0.02

Q1'25

Missed

by $0.01

Q4'24

Beat

by $0.03

Q3'24

Beat

by $0.02

The last earnings report on July 29 showed earnings per share of -20 cents, missing the estimate of -18 cents. With 241.38K shares outstanding, the current market capitalization sits at 159.00M.

View a ticker or compare two or three

Compare

CRDF

Setup

Buy or SellView

Daily Signalchanged days ago

Gain/Loss if bought

View Trends For CRDF
(Try 14 days for Free)

Interact to see
Advertisement

A.I.Advisor

published price charts

These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. CRDF showed earnings on July 29, 2025. You can read more about the earnings report here.

View AI-Driven Trading

A.I. Advisor

published General Information

General Information

a cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors

Industry Biotechnology

Profile

Fundamentals

Details

Industry

N/A

Address

11055 Flintkote Avenue

Phone

+1 858 952-7570

Employees

Web

https://www.cardiffoncology.com